微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2017, Vol. 9 ›› Issue (3): 190-195.doi: 10.3969/j.issn.1674-5671.2017.03.06

• 临床研究 • 上一篇    下一篇

Survivin、NF-κB、VEGFR-2在食管小细胞癌中的表达及其与甲磺酸阿帕替尼疗效的相关性

  

  1. 山东省日照市人民医院  药剂科 肿瘤科
  • 出版日期:2017-06-25 发布日期:2017-08-02
  • 通讯作者: 孟令新 menglx001623@163.com
  • 基金资助:

    山东省医药卫生科技发展计划资助项目（2016WS0329）；济宁医学院青年教师科研扶持基金资助项目（JY2016KJ050Y）

Expression of Survivin,NF-κB and VEGFR-2 and their relationship with Apatinib therapy in small-cell carcinoma of esophagus

 

  • Online:2017-06-25 Published:2017-08-02

PDF (PC)

356

赞

摘要：

目的　探讨食管小细胞癌Survivin、NF-κB和血管内皮细胞生长因子受体2（vascular endothelial growth factor receptor 2，VEGFR-2）的表达及其与甲磺酸阿帕替尼疗效的相关性。方法 采用免疫组化SABC法检测36例食管小细胞癌Survivin、NF-κB、VEGFR-2的表达，并计数微血管密度（microvascular density，MVD）和微淋巴管密度（micro-lymphatic vessel density，MLVD），分析各指标与MVD、MLVD计数及甲磺酸阿帕替尼疗效的关系。结果 Survivin、NF-κB和VEGFR-2在食管小细胞癌中的阳性表达率分别为22.22%、66.67%和80.56%。Survivin、MLVD与食管小细胞癌淋巴结转移和浸润深度均无相关性（Ｐ＞0.05）。VEGFR-2、NF-κB表达及MVD与淋巴结转移密切相关（Ｐ＜0.05），与浸润深度无关（Ｐ＞0.05）。NF-κB、VEGFR-2表达阳性者MVD明显高于阴性表达者（Ｐ＜0.05）。NF-κB、VEGFR-2阳性组患者口服甲磺酸阿帕替尼治疗的疗效优于阴性组，而Survivin阳性、阴性组疗效差异无统计学意义（Ｐ＞0.05）。结论 食管小细胞癌中的VEGFR-2、NF-κB表达及MVD均与淋巴结转移密切相关，NF-κB、VEGFR-2阳性表达可作为口服甲磺酸阿帕替尼靶向治疗的生物学参考靶标。

关键词: 食管肿瘤, Survivin, NF-κB, VEGFR-2, 微血管密度, 微淋巴管密度, 甲磺酸阿帕替尼

Abstract:

Objective To investigate the expression of Survivin，NF-κB，and VEGFR-2 as well as their relationships with treatment effects of Apatinib and with microvascular density and micro-lymphatic vessel density in small-cell carcinoma of esophagus. Methods Immunohistochemistry was used to assess expression of Survivin，NF-κB and VEGFR-2 as well as microvascular density and micro-lymphatic vessel density in 36 cases of small-cell carcinoma of the esophagus. The results were compared with Apatinib treatment efficacy. Results Rates of positive expression were 22.22% for Survivin，66.67% for NF-κB and 80.56% for VEGFR-2. Lymphatic metastasis did not correlate with expression of Survivin，micro-lymphatic vessel density or tumor invasion depth. Lymphatic metastasis did correlate with expression of VEGFR-2，NF-κB and microvascular density，but not with tumor invasion depth. Microvascular density was higher in samples positive for NF-κB expression than in negative samples. Treatment effects of Apatinib were better in patients positive for NF-κB and VEGFR-2 expression than in expression-negative patients；treatment effects，however，did not vary with Survivin expression status. Conclusion Tumor lymphatic metastasis correlated significantly with VEGFR-2，NF-κB and microvascular density. NF-κB and VEGFR-2 may play an important role in small-cell carcinoma and may be useful biomarkers in Apatinib therapy.

Key words: Esophageal neoplasms, Survivin, NF-κB, VEGFR-2, Microvascular density, Micro-lymphatic vessel density, Apatinib